Split Biosciences (which also announced a rebrand to Parse Biosciences), a Seattle, WA-based company providing researchers scalable and flexible single cell sequencing solutions, raised $7M in Series A funding.
The round was led by Bioeconomy Capital with participation from new and existing angel investors.
The company intends to use the funds to continue scaling the commercial roll-out of its Whole Transcriptome Kit.
Led by Alex Rosenberg, CEO, and Charlie Roco, CTO, Parse Biosciences is a company which is advancing Whole Transcriptome Kit, which enables researchers to profile up to 100,000 cells in parallel across up to 48 samples. In addition to increased scalability, the technology also provides researchers with higher data quality and enables them to increase gene detection in individual cells, while reducing confounding artifacts that are common in single cell sequencing experiments.
The Whole Transcriptome Kit is already used in 40 labs across the country, providing these researchers with improved resolution and throughput in their experiments. The company also supplies a computational pipeline which generates an experimental report along with a gene-cell count matrix and other processed data that integrates into existing open source tools, such as Seurat and Scanpy.
FinSMEs
26/01/2021